New Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof.

Similar documents
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

PCSK9 Agents Drug Class Prior Authorization Protocol

Study 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018

Study 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results

Drug Class Monograph

Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials

New Guidelines in Dyslipidemia Management

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Disclosures. Objectives 2/11/2017

Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Landmesser U et al. Eur Heart J 2017; /eurheartj/ehx549

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk

Review of guidelines for management of dyslipidemia in diabetic patients

Contemporary management of Dyslipidemia

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA

Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin

Eyes on Korean Data: Lipid Management in Korean DM Patients

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors

No relevant financial relationships

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary

Juxtapid (lomitapide)

Deep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City

4 th and Goal To Go How Low Should We Go? :

PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Review current guideline recommendations for lipid-lowering therapy

Drug Prior Authorization Guideline PCSK9 Inhibitors -

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes

New Guidelines in Dyslipidemia Management

ATP IV: Predicting Guideline Updates

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

PCSK9 Inhibitors and Modulators

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Dyslipidemia Treatment in 2016 Novel Agents Combination Therapies Statin Intolerance

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

Treatment of Atherosclerosis in 2007

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

B. Patient has not reached the percentage reduction goal with statin therapy

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018

Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.

Praluent. Praluent (alirocumab) Description

Approach to Dyslipidemia among diabetic patients

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017

Lipids: new drugs, new trials, new guidelines

CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?

Cholesterol Management Roy Gandolfi, MD

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

HYPERCHOLESTEROLEMIA

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

LDL and the Benefits of Statin Therapy

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

PCSK9 Inhibitors: Promise or Pitfall?

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine

MS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators

No relevant financial relationships

Copyright 2017 by Sea Courses Inc.

Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

What do the guidelines say about combination therapy?

March 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges

How would you manage Ms. Gold

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Lipid Management 2013 Statin Benefit Groups

Repatha. Repatha (evolocumab) Description

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Repatha. Repatha (evolocumab) Description

Kynamro. Kynamro (mipomersen) Description

Latest Guidelines for Lipid Management

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017

Company Overview. September 2018 NASDAQ: MDGL

Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia

REPATHA (PCSK9 INHIBITORS)

Problem patients in primary care Patient 4: Peripheral artery disease

Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

New Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof. Maciej Banach Łódź, PL

According to : Central Intelligence Agency". Retrieved 2012-10-07; updated 2016.

According to: Wall chart on Population Ageing and Development 2012 (United Nation Population Devision)

According to: Wall chart on Population Ageing and Development 2012 (United Nation Population Devision)

POLSENIOR cohort study (2011) Hypercholesterolemia ( 190 mg/dl) prevalence in the elderly ( 65) in Poland 56% 66% 62% All patients 65+ M W Together Bledowski P., et al. Exp Gerontol. 2011 Dec;46(12):1003-9.

Total cholesterol levels depending on sex and age W W Proportion of patients prescribed cholesterol lowering drugs and mean cholesterol concentration of treated and untreated patients (treatment-risk paradox) Sheppard J P et al. BMJ 2012;345:bmj.e4535 Bledowski P., et al. Exp Gerontol. 2011 Dec;46(12):1003-9.

All-cause mortality and cholesterol in the elderly Low TC (<5.5 mmol/l / 213 mg/dl) is associated with increased mortality among 80+-year olds. There was no clear optimal level of cholesterol in 80+-year-old people. Some studies found the intermediate level of the cholesterol (around 6 mmol/l / 232 mg/dl) to be associated with the lowest mortality, but this was not consistent. Few data on TC and mortality are available on 80+-year olds. Petersen L K et al. Age Ageing 2010;39:674-680

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016 Banach M, et al. Arch Med. Sci 2017;13(1):1-45.

Waterfall plot for individual trial participants allocated to rosuvastatin 20 mg for the per cent change in low-density lipoprotein cholesterol (left) and concordant incident event rates (per 1000 person-years) for the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin primary endpoint (right). Paul M Ridker et al. Eur Heart J 2016;eurheartj.ehw046 Published on behalf of the European Society of Cardiology. All rights reserved. The Author 2016. For permissions please email: journals.permissions@oup.com.

Jackievicius C, et al. JAMA 2002;288(4):462 467.

Kutner J.S., et al. JAMA Intern Med. 2015 May; 175(5): 691 700.

CV Event Rate (%) We Need a Drug that Helps High-risk Patients to Achieve LDL-C Goal 30 25 20 15 10 5 0 40 (1.0) LDL-C goal* 60 (1.6) 80 (2.1) Patient receives PCSK9 inhibitor Patient adds XXX 60% reduction in LDL-C Patient adds ezetimibe 15% reduction in LDL-C 100 (2.5) 120 (3.1) 140 (3.6) Patient receives first statin 35% reduction in LDL-C Patient titrates statin LDL-C Achieved, mg/dl (mmol/l) 8% reduction in LDL-C 160 (4.1) 180 (4.7) Illustrative High-risk patient first diagnosed With statin intolerance 200 (5.2) *LDL-C goal for high-risk and very high-risk patients as defined by ESC/EAS guidelines for the management of dyslipidemias. Reiner Z, et al. Eur Heart J 2011;32:1769 818.

Conditions and Populations at High Risk of Statin Intolerance Liver diseases ALT > 3x ULN occurs in < 0.5% for moderatedose statins and rosuvastatin at all doses, and about 1% for 80 mg of atorvastatin or simvastatin. However, this might be an overstatement because, in most studies, the incidence of ALT increase was similar in statin and placebo patients, and because almost 50% of dyslipidaemic patients requiring statin treatment might have had established NAFLD. Elderly patients CKD Rheumatic diseases Banach M, et al. Arch Med Sci 2015;11:1 23. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CKD, chronic kidney disease; CLD, chronic liver disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; KDIGO, Kidney Disease: Improving Global Outcomes; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis.

Changes in the proportion of individuals in different LDL-C ranges between the studies performed in 2004, 2006 and LIPIDOGRAM2015 cohort study. 2015 2006 2004 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% LDL<=70 (70-100] (100-115] (115-160] (160-190] LDL>190 Based on the analysis of 33689 patients we found 199 patients with LDL-C 330 mg/dl (8 pts.) (including 31 patients with positive clinical personal history of premature CAD - 10 pts. in total), and 228 subjects with LDL-C: 250 329 mg/dl and positive clinical personal history of premature CAD (7 pts. in total in DLCN criteria). The estimated overall prevalence of probable/definite FH ( 7 pts.) was 1,27% or 1 in 79, suggesting 400,457 Polish adults with FH or at the high risk of FH diagnosis.

LS mean (SE) % change in calculated LDL-C from baseline to Week 24 Change in LDL-C from Baseline to Week 24 According to HeFH status (ITT) Alirocumab Placebo 20 HeFH population Non-HeFH population 10 0-10 -20-30 -40-50 -60-70 LS mean difference vs. placebo: -56.3±1.9% 7.0±2.4% -0.5±1.1% 63.2% -62.1±0.8% Interaction p-value 0.6038 61.5% 21

Percent change in LDL-C for (a) Placebo-controlled and (b) Ezetimibe-controlled studies by Age

Percent change in ApoB for (a) Placebo-controlled and (b) Ezetimibe-controlled studies by Age

Percent change in TC for (a) Placebo-controlled and (b) Ezetimibe-controlled studies by Age

Percent change in Lp(a) for (a) Placebo-controlled and (b) Ezetimibe-controlled studies by Age

Adverse Events (Parent Studies) Koren MJ, et al. ACC 2015 presentation.

Adverse Events (Extension Studies) PCSK9 inhibition with evolocumab potently reduced LDL-C and other atherogenic lipid parameters in patients 65 or 75 years old. The incidence of adverse events in the elderly population was comparable between those receiving evolocumab or control. Koren MJ, et al. ACC 2015 presentation.

ETC-1002: PHASE 2 CLINICAL STUDIES Study Number 003 005 006 007 008 009 014 Short Title (N=total/ETC-1002 treated) Phase 2a in Patients with Hypercholesterolemia (N=177/133) Phase 2a in Patients with Hypercholesterolemia and Type 2 Diabetes (N=60/30) Phase 2a in Patients with Hypercholesterolemia and a History of Statin Intolerance (N=56/37) Phase 2a in Patients with Hypercholesterolemia Added-on to Atorvastatin 10 mg (N=58/42) Phase 2b in Patients with Hypercholesterolemia with or without Statin Intolerance vs. Ezetimibe (N=349/249) Phase 2b in Patients with Hypercholesterolemia while on Stable Statin Therapy (N=134/88) Phase 2a in Patients with Hypercholesterolemia and Hypertension (N=143/72) ' LDL-C Lowering* (pbo corrected) Dose Range (mg) Treatment Duration Up to 27% (25%) 40, 80, 120 12 Wks 43% (39%) 80, 120 4 Wks 32% (29%) 22% (22%) Up to 30% (1002) Up to 48% (1002 + ezetimibe) 60, 120, 180, 240 60, 120, 180, 240 120, 180, 120 + ezetimibe, 180 + ezetimibe 8 Wks 8 Wks 12 Wks 24% (20%) 120, 180 12 Wks 21% (24%) 180 6 Wks *Average LDL-C % Change from Baseline 35

Bempedoic Acid Phase 3 CLEAR Program LDL-C Lowering Indication (Total N=~3400): ASCVD and/or HeFH CLEAR Harmony; Long-Term, N=2233 CLEAR Wisdom; High Risk, N=750 52 weeks safety 52 weeks safety / 12 weeks LDL-C Open-Label Extension (OLE) 78 weeks safety Statin Intolerant CLEAR Serenity; SI, N=300 CLEAR Tranquility; SI, +EZ, N=225 24 weeks safety / 12 weeks LDL-C 12 weeks LDL-C Four (4) pivotal Phase 3 studies designed to enroll ~3400 high risk patients randomized 2:1 At high CV risk with hypercholesterolemia on optimized background lipid-modifying therapy (with ASCVD and/or HeFH) Only able to tolerate less than the lowest approved daily starting dose of a statin and considered statin intolerant Phase 3 program adequate to support approval for an LDL-C lowering indication for bempedoic acid 36

Randomization (T1) CLEAR Outcomes (1002-043) Global CVOT Study Design A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT SP & PP Patients with Elevated LDL-C and Statin Intolerance Bempedoic acid 180 mg (n=6302) Placebo (n=6302) Study Phase Week Study Visit -5 S1 Screen Period -4 S2 Single Blind Placebo Run in 0 T1 Double Blind Treatment Period Evaluating MACE/LDL-C Reduction/Safety ~4.75 years After T1 Visits at months 1, 3 and 6 alternating phone visits and clinic visits every 3 months thereafter 37

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECT OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE WHO ARE UNABLE TO TOLERATE STATIN THERAPY (1002-043) STUDY CONCEPT Primary Objective: To evaluate whether bempedoic acid (ETC-1002) 180 mg/day reduces the risk of CV disease in patients with ASCVD who are unable to tolerate statin therapy. Patients with high risk ASCVD and statin intolerance (n=10,000) Allowed background lipid therapies: Approved non-statin drugs or supplements Per definition of statin intolerance, use of less than the approved starting dose of a statin is also permitted if tolerated Baseline LDL-C >110 mg/dl Mean treatment duration ~3 years 38

39 aaaaaaaaa aaaaaaa

40 aaaaaaaaa aaaaaaa

41 aaaaaaaaa aaaaaaa

Mean Age 64 (34-85) aaaaaaaaa aaaaaaa